This RNA-guided endonuclease system allows the introduction of patient-specific mutations or deletions in tumor suppressor genes and oncogenes, such as TP53, EGFR, and PTEN, directly into glioma cells or animal germlines [51]. This evidence concerns the gene EGFR and glioma.